EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients

Alicja Puszkiel, Florence Dalenc, Naïma Tafzi, Pierre Marquet, Marc Debled, William Jacot, Laurence Venat-Bouvet, Catherine Ferrer, Nadia Levasseur, Rodolphe Paulon, Jérôme Dauba, Alexandre Evrard und 5 weitere

European Journal of Pharmaceutical Sciences · 2024

DOI: 10.1016/j.ejps.2024.106809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2024. Verfasst von Alicja Puszkiel und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier - Toulouse III, 2 Avenue Hubert Curien, Toulouse 31100, France. Hauptthemen laut MEDLINE: Letrozole, Breast Neoplasms, Medication Adherence, Aromatase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Letrozole, an aromatase inhibitor metabolised via CYP2A6 and CYP3A4/5 enzymes, is used as adjuvant therapy for women with hormone receptor (HR)-positive early breast cancer. The objective of this study was to quantify the impact of CYP2A6 genotype on letrozole pharmacokinetics (PK), to identify non-adherent patients using a population approach and explore the possibility of a relationship between non-adherence and early relapse. METHODS: Breast cancer patients enrolled in the prospective PHACS study (ClinicalTrials.gov NCT01127295) and treated with adjuvant letrozole 2.5 mg/day were included. Trough letrozole concentrations (Css,trough) were measured every 6 months for 3 years by a validated LC-MS/MS method. Concentration-time data were analysed using non-linear mixed effects modelling. Three methods were evaluated for identification of non-adherent subjects using the base PK model. RESULTS: 617 patients contributing 2534 plasma concentrations were included and led to a one-compartment PK model with linear absorption and elimination. Model-based methods identified 28 % of patients as non-adherent based on high fluctuations of their Css,trough compared to 3 % based on patient declarations. The covariate analysis performed in adherent subjects revealed that CYP2A6 intermediate (IM) and slow metabolisers (SM) had 21 % (CI95 % = 12 - 30 %) and 46 % (CI95 % = 41 - 51 %) lower apparent clearance, respectively, compared to normal and ultrarapid metabolisers (NM+UM). Early relapse (19 patients) was not associated with model-estimated, concentration-based or declared adherence in the total population (p = 0.41, p = 0.37 and p = 0.45, respectively). CONCLUSIONS: These findings will help future investigations focusing on the exposure-efficacy relationship for letrozole in adjuvant setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LetrozoleBreast NeoplasmsMedication AdherenceAromatase InhibitorsHumansFemaleMiddle AgedAgedAdultChemotherapy, AdjuvantModels, BiologicalProspective StudiesReceptors, EstrogenAntineoplastic AgentsAged, 80 and over

Stichwörter der Autor:innen

AdherenceCYP2A6CYP3A4/5LetrozoleNon-linear mixed-effects modellingPharmacokinetics

Substanzen

LetrozoleAromatase InhibitorsReceptors, EstrogenAntineoplastic Agents

Autor:innen und Institutionen

  • Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier - Toulouse III, 2 Avenue Hubert Curien, Toulouse 31100, France.
  • Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.
  • Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France.
  • Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
  • Institut du Cancer de Montpellier, ICM, Université de Montpellier, IRCM, Inserm U1194, Montpellier, France.
  • Department of Medical Oncology, CHU Limoges, Limoges, France.

Zitieren

APA

Puszkiel, A., Dalenc, F., Tafzi, N., Marquet, P., Debled, M., Jacot, W., Venat-Bouvet, L., Ferrer, C., Levasseur, N., Paulon, R., Dauba, J., Evrard, A., Mauriès, V., Filleron, T., Chatelut, E., Thomas, F., & White-Koning, M. (2024). Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2024.106809

Vancouver

Puszkiel A, Dalenc F, Tafzi N, Marquet P, Debled M, Jacot W, et al. Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients. European Journal of Pharmaceutical Sciences. 2024. doi:10.1016/j.ejps.2024.106809

BibTeX
@article{Puszkiel2024,
  author = {Puszkiel, Alicja and Dalenc, Florence and Tafzi, Naïma and Marquet, Pierre and Debled, Marc and Jacot, William and Venat-Bouvet, Laurence and Ferrer, Catherine and Levasseur, Nadia and Paulon, Rodolphe and Dauba, Jérôme and Evrard, Alexandre and Mauriès, Vincent and Filleron, Thomas and Chatelut, Etienne and Thomas, Fabienne and White-Koning, Melanie},
  title = {Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients},
  journal = {European Journal of Pharmaceutical Sciences},
  year = {2024},
  doi = {10.1016/j.ejps.2024.106809}
}
Kostenlos starten →